Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome

References

• Jayakody DA, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol 2014;165:609-17
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi M, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and pattern of disease expression in a color of 1000 patients. Arthritis Rheum 2002;46:1019-27
   PubMed Web of Science ®Google Scholar
• Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 2013;65:1869-73
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010;9:A299-304
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Andreoli L, Banzato A, et al. The association between antiphospholipid antibodies and related clinical outcomes: a critical review of the literature. Arthritis Rheum 2013;65:S1129
   Google Scholar
• Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a meta-analysis. J Rheumatol 2006;33:2214-21
   PubMed Web of Science ®Google Scholar
• Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011;128:77-85
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012;64:2311-18
   PubMed Web of Science ®Google Scholar
• Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010;19:58-64
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Calligaro A, Hoxha A, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 2010;62:302-7
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology 2011;50:1684-9
   PubMed Web of Science ®Google Scholar
• Andreoli L, Fredi M, Nalli C, et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmunity 2012;38:197-208
   Web of Science ®Google Scholar
• Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of the antiphospholipid syndrome: understanding the autoantibodies. Nat Rev Rheum 2011;7:330-9
   PubMed Web of Science ®Google Scholar
• Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;14:1033-44
   Google Scholar
• De Carolis S, Botta A, Santucci S, et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 2012;21:776-8
   PubMed Web of Science ®Google Scholar
• Reggia R, Ziglioli T, Andreoli L, et al. Primary antiphospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? Rheumatology 2012;51:2186-90
   PubMed Web of Science ®Google Scholar
• De Carolis S, Botta A, Santucci S, et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allerg Immunol 2010;38:116-24
   PubMed Web of Science ®Google Scholar
• D’Ippolito S, Meroni PL, Koike T, et al. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 2014;13(9):901-8
   PubMed Web of Science ®Google Scholar
• de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th International congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014;13:795-813
   PubMed Web of Science ®Google Scholar
• Danza A, Ruiz-Irastorza G, Khamashta MA. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol 2012;26:65-76
   PubMed Web of Science ®Google Scholar
• Lubbe WF, Butler WS, Palmer SJ, et al. Foetal survival after prednisolone suppression of maternal lupus-anticoagulant. Lancet 1983;18:1361-3
   Google Scholar
• Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent foetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989;60:439-43
   Google Scholar
• Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005(2): CD002859
   PubMed Web of Science ®Google Scholar
• Elder MG, de Swiet M, Robertson A, et al. Low dose aspirin in pregnancy. Lancet 1988;1:410
   PubMed Web of Science ®Google Scholar
• Carmona F, Font J, Azulay M, et al. Risk factors associated with foetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001;46:274-9
   PubMed Web of Science ®Google Scholar
• Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993;169:1411-17
   PubMed Web of Science ®Google Scholar
• Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131-6
   PubMed Web of Science ®Google Scholar
• Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997;6:509-13
   PubMed Web of Science ®Google Scholar
• Huong DL, Wechsler B, Bletry O, et al. A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 2001;28:2025-30
   PubMed Web of Science ®Google Scholar
• Munoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999;29:182-90
   PubMed Web of Science ®Google Scholar
• Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000;183:1008-12
   PubMed Web of Science ®Google Scholar
• Tulppala M, Marttunen M, Soderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997;12:1567-72
   PubMed Web of Science ®Google Scholar
• Rosove MH, Tabsh K, Wasserstrum N, et al. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990;75:630-4
   PubMed Web of Science ®Google Scholar
• Cowchock FS, Reece EA, Baldan D, et al. Repeated foetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 1992;166:1318-27
   PubMed Web of Science ®Google Scholar
• Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9
   PubMed Web of Science ®Google Scholar
• Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7
   PubMed Web of Science ®Google Scholar
• Fishman P, Falach-Vaknin E, Sredni B, et al. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol 1996;35:80-4
   PubMed Web of Science ®Google Scholar
• Di Simone N, Meroni PL, D’asta M, et al. Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update 2007;13:189-96
   PubMed Web of Science ®Google Scholar
• Guerin J, Sheng Y, Reddel S, et al. Heparin inhibits the binding of 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. J Biol Chem 2002;277:2644-9
   PubMed Web of Science ®Google Scholar
• Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced foetal loss by inhibiting complement activation. Nat Med 2004;10:1222-6
   PubMed Web of Science ®Google Scholar
• D’Ippolito S, Marana R, Di Nicuolo F, et al. Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)–mediated inhibition of endometrial angiogenesis. PLoS One 2012;7(1):e29660
   PubMed Web of Science ®Google Scholar
• de Carvalho JF, de Oliveira RM, Rodrigues CE, et al. Heparin increases HLA-G levels in primary antiphospholipid syndrome. Clin Dev Immunol 2012;2012:232390
   PubMedGoogle Scholar
• De Sancho MT, Khalid S, Christos PJ. Outcomes in women receiving low-molecular weight heparin during pregnancy. Blood Coagul Fibrinolysis 2012;23:51-755
   PubMed Web of Science ®Google Scholar
• Mak A, Cheung M W, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010;49:281-8
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010;115:1256-62
   PubMed Web of Science ®Google Scholar
• Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol 2009;36:279-87
   PubMed Web of Science ®Google Scholar
• Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13
   PubMed Web of Science ®Google Scholar
• Roberge S, Giguere Y, Villa P, et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012;29:551-6
   PubMed Web of Science ®Google Scholar
• Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402-14
   PubMed Web of Science ®Google Scholar
• Rodger MA, Carrier M, Le Gal G, et al. Meta-analysis of low-molecular weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014;123(6):822-8
   PubMed Web of Science ®Google Scholar
• Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565
   PubMed Web of Science ®Google Scholar
• Pauzner R, Dulitzki M, Langevitz P, et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 2001;86:1379-84
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:844S-86S
   PubMed Web of Science ®Google Scholar
• Horlocker T, Wedel D, Rowlingson J, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010;35:64-101
   PubMed Web of Science ®Google Scholar
• Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209
   PubMed Web of Science ®Google Scholar
• Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic events in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-AOS observational study. Blood 2012;119:2624-32
   PubMed Web of Science ®Google Scholar
• Martinez-Zamora MA, Peralta S, Creus M, et al. Risk of thrombotic events after recurrent abortion in anti-phospholipid syndrome: a case-control study. Ann Rheum Dis 2012;71:61-6
   PubMed Web of Science ®Google Scholar
• Erkan D, Merrill JT, Yazici Y, et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001;44:1466-9
   PubMed Web of Science ®Google Scholar
• Erkan D, Patel S, Nuzzo M, et al. Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. Rheumatology 2008;47:23-7
   Web of Science ®Google Scholar
• Carreras LO, Perez GN, Vega H, et al. Lupus anticoagulant and recurrent foetal loss: successful treatment with gammaglobulin. Lancet 1988;2:393-4
   PubMed Web of Science ®Google Scholar
• Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011;117:6948-51
   PubMed Web of Science ®Google Scholar
• Bontadi A, Ruffatti A, Tison T, et al. Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher 2012;27:200-4
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Salvan E, del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thromb Haemost 2014;112(4. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;26:729-34
   PubMedGoogle Scholar
• Noble LS, Kutteh WH, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005;83:684-90
   PubMed Web of Science ®Google Scholar
• Fouda U, Sayed AM, Abdou AM, et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynecol Obstet 2011;112:211-15
   PubMed Web of Science ®Google Scholar
• Ensom MH, Stephenson MD. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. J Soc Gynecol Investig 2004;11:377-83
   PubMedGoogle Scholar
• Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996;35:402-7
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Gervasi MT, Favaro M, et al. Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study. Clin Exp Rheumatol 2011;29:551-4
   PubMed Web of Science ®Google Scholar
• Boffa MC, Boinot C, De Carolis S, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Hasemost 2009;102:25-8
   PubMed Web of Science ®Google Scholar
• Silver RM, Parker CB, Reddy UM, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol 2013;122:641-57
   PubMed Web of Science ®Google Scholar
• Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011;90:1428-33
   PubMed Web of Science ®Google Scholar
• Mekinian A, Loire-Berson P, Nicaise-Roland P, et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 2012;94:222-6
   PubMed Web of Science ®Google Scholar
• Gardiner C, Hills J, Machin SJ, et al. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013;22:18-25
   PubMed Web of Science ®Google Scholar
• Chaleur C, Galanaud JP, Alonso S, et al. Observational study of pregnant women with a previous spontaneous abortion before 10th gestational week with and without antiphospholipid antibodies. J Thromb Haemost 2010;8:669-706
   PubMed Web of Science ®Google Scholar
• Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing group of the antiphospholipid antibody treatment trial. Am J Obstet Gynecol 1997;176:1099-100
   PubMed Web of Science ®Google Scholar
• Del Ross T, Ruffatti A, Visentin MS, et al. Treatment of 139 pregnancies in anti-phospholipid positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol 2013;40:425-9
   PubMed Web of Science ®Google Scholar
• Soh MC, Pasupathy D, Gray G, et al. Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes. Rheumatology 2013;52:1642-7
   PubMed Web of Science ®Google Scholar
• Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011;3:77-80
   Google Scholar
• de Jesus GR, Rodrigues G, de Jesus NR, Levy RA. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep 2014;16:403
   PubMed Web of Science ®Google Scholar
• Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancies: double-blind and placebo-controlled study. Lupus 2001;10:401-4
   PubMed Web of Science ®Google Scholar
• de la Torre YM, Pregnolato F, D’Amelio F, et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun 2012;38:J209-15
   PubMed Web of Science ®Google Scholar
• Agostinis C, Durigutto P, Sblattero D, et al. A non complement-fixing antibody to b2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood 2014;123:3478-87
   PubMed Web of Science ®Google Scholar
• Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014;123:404-13
   PubMed Web of Science ®Google Scholar
• Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 2014;16:209
   PubMed Web of Science ®Google Scholar